Rhythm Pharmaceuticals (RYTM) Other Non Operating Income (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Other Non Operating Income data on file, last reported at -$1.7 million in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$1.7 million, down 164.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $203000.0 (down 72.79% YoY), and the FY2025 annual result was $1.3 million, down 85.8% from the prior year.
• Other Non Operating Income retreated to -$1.7 million in Q1 2026 per RYTM's latest filing, from $57000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $1.6 million in Q2 2025 and troughed at -$1.7 million in Q1 2026.
• A 5-year average of $42062.5 and a median of -$22000.0 in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income jumped 2040.74% in 2024, then plunged 222.9% in 2025.
• A 5-year view of Other Non Operating Income shows it stood at -$420000.0 in 2022, then surged by 233.1% to $559000.0 in 2023, then surged by 94.63% to $1.1 million in 2024, then sank by 94.76% to $57000.0 in 2025, then slumped by 3089.47% to -$1.7 million in 2026.
• Business Quant data shows RYTM's Other Non Operating Income at -$1.7 million in Q1 2026, $57000.0 in Q4 2025, and $274000.0 in Q3 2025.